|
1
|
Lazcano-Ponce EC, Miquel JF, Muñoz N, et
al: Epidemiology and molecular pathology of gallbladder cancer. CA
Cancer J Clin. 51:349–364. 2001. View Article : Google Scholar
|
|
2
|
Reddy SK and Clary BM: Surgical management
of gallbladder cancer. Surg Oncol Clin N Am. 18:307–324. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chakravarty KD, Yeh CN, Jan YY and Chen
MF: Factors influencing long-term survival in patients with T3
gallbladder adenocarcinoma. Digestion. 79:151–157. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ishii H, Furuse J, Yonemoto N, et al:
Chemotherapy in the treatment of advanced gallbladder cancer.
Oncology. 66:138–142. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mahantshetty UM, Palled SR, Engineer R, et
al: Adjuvant radiation therapy in gallbladder cancers: 10 years
experience at Tata Memorial Hospital. J Cancer Res Ther. 2:52–56.
2006. View Article : Google Scholar
|
|
6
|
Maniotis AJ, Folberg R, Hess A, et al:
Vascular channel formation by human melanoma cells in vivo and in
vitro: vasculogenic mimicry. Am J Pathol. 155:739–752. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Warso MA, Maniotis AJ, Chen X, et al:
Prognostic significance of periodic acid-Schiff-positive patterns
in primary cutaneous melanoma. Clin Cancer Res. 7:473–477.
2001.PubMed/NCBI
|
|
8
|
Tian F, Zhang X, Tong Y, et al: PE, a new
sulfated saponin from sea cucumber, exhibits anti-angiogenic and
anti-tumor activities in vitro and in vivo. Cancer Biol Ther.
4:874–882. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhou YX and Huang YL: Antiangiogenic
effect of celastrol on the growth of human glioma: an in vitro and
in vivo study. Chin Med J (Engl). 122:1666–1673. 2009.
|
|
10
|
Zhang JT, Fan YZ, Chen CQ, Zhao ZM and Sun
W: Norcantharidin: A potential antiangiogenic agent for gallbladder
cancers in vitro and in vivo. Int J Oncol. 40:1501–1514. 2012.
|
|
11
|
Zhang S, Li M, Gu Y, et al: Thalidomide
influences growth and vasculogenic mimicry channel formation in
melanoma. J Exp Clin Cancer Res. 27:602008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cong R, Sun Q, Yang L, et al: Effect of
Genistein on vasculogenic mimicry formation by human uveal melanoma
cells. J Exp Clin Cancer Res. 28:1242009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fu D, He X, Yang S, et al: Zoledronic acid
inhibits vasculogenic mimicry in murine osteosarcoma cell line in
vitro. BMC Musculoskelet Disord. 12:1462011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen LX, He YJ, Zhao SZ, et al: Inhibition
of tumor growth and vasculogenic mimicry by curcumin through
downregulation of the EphA2/PI3K/MMP pathway in a murine choroidal
melanoma model. Cancer Biol Ther. 11:229–235. 2011. View Article : Google Scholar
|
|
15
|
Chen HX and Cleck JN: Adverse effects of
anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol.
6:465–477. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Higa GM and Abraham J: Biological
mechanisms of bevacizumab-associated adverse events. Expert Rev
Anticancer Ther. 9:999–1007. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
van der Schaft DW, Seftor RE, Seftor EA,
et al: Effects of angiogenesis inhibitors on vascular network
formation by human endothelial and melanoma cells. J Natl Cancer
Inst. 96:1473–1477. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
McCawley LJ and Matrisian LM: Matrix
metalloproteinases: multifunctional contributors to tumor
progression. Mol Med Today. 6:149–156. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Stetler-Stevenson WG: Matrix
metalloproteinases in angiogenesis: a moving target for therapeutic
intervention. J Clin Invest. 103:1237–1241. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sood AK, Fletcher MS, Coffin JE, et al:
Functional role of matrix metalloproteinases in ovarian tumor cell
plasticity. Am J Obstet Gynecol. 190:899–909. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hess AR, Seftor EA, Seftor RE and Hendrix
MJ: Phosphoinositide 3-kinase regulates membrane type 1-matrix
metalloproteinase (MMP) and MMP-2 activity during melanoma cell
vasculogenic mimicry. Cancer Res. 63:4757–4762. 2003.PubMed/NCBI
|
|
22
|
Hendrix MJ, Seftor EA, Kirschmann DA,
Quaranta V and Seftor RE: Remodeling of the microenvironment by
aggressive melanoma tumor cells. Ann N Y Acad Sci. 995:151–161.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Albini A, Melchiori A, Santi L, et al:
Tumor cell invasion inhibited by TIMP-2. J Natl Cancer Inst.
83:775–779. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Seftor RE, Seftor EA, Koshikawa N, et al:
Cooperative interactions of laminin 5 gamma2 chain, matrix
metalloproteinase-2, and membrane type-1-matrix/ metalloproteinase
are required for mimicry of embryonic vasculogenesis by aggressive
melanoma. Cancer Res. 61:6322–6327. 2001.PubMed/NCBI
|
|
25
|
Fan YZ, Sun W, Zhang WZ and Ge CY:
Vasculogenic mimicry in human primary gallbladder carcinoma and
clinical significance thereof. Zhonghua Yi Xue Za Zhi. 87:145–149.
2007.(In Chinese). PubMed/NCBI
|
|
26
|
Sun W, Shen ZY, Zhang H, Fan YZ, Zhang WZ,
Zhang JT, Lu XS and Ye C: Overexpression of HIF- 1α in primary
gallbladder carcinoma and its relation to vasculogenic mimicry and
unfavourable prognosis. Oncol Rep. 27:1990–2002. 2012.PubMed/NCBI
|
|
27
|
Sun W, Fan YZ, Zhang WZ and Ge CY: A pilot
histomorphology and hemodynamic of vasculogenic mimicry in
gallbladder carcinomas in vivo and in vitro. J Exp Clin Cancer Res.
30:462011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lu XS, Sun W, Ge CY, Zhang WZ and Fan YZ:
Contribution of the PI3-K/MMPs/Ln-5γ2 and EphA2/FAK/Paxillin
signaling pathways to tumor growth and vasculogenic mimicry of
gallbladder carcinomas. Int J Oncol. 42:2103–2115. 2013.PubMed/NCBI
|
|
29
|
Wang GS: Medical uses of mylabris in
ancient China and recent studies. J Ethnopharmacol. 26:147–162.
1989. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu J, Gao J and Liu X: Advances in the
study of Cantharidin and its derivatives. Zhong Yao Cai.
26:453–455. 2003.PubMed/NCBI
|
|
31
|
Ho YP, To KK, Au-Yeung SC, et al:
Potential new antitumor agents from an innovative combination of
demethylcantharidin, a modified traditional Chinese medicine, with
a platinum moiety. J Med Chem. 44:2065–2068. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yang EB, Tang WY, Zhang K, Cheng LY and
Mack PO: Norcantharidin inhibits growth of human HepG2
cell-transplanted tumor in nude mice and prolongs host survival.
Cancer Lett. 117:93–98. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yi SN, Wass J, Vincent P and Iland H:
Inhibitory effect of norcantharidin on K562 human myeloid leukemia
cells in vitro. Leuk Res. 15:883–886. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
An WW, Wang MW, Tashiro S, Onodera S and
Ikejima T: Norcantharidin induces human melanoma A375-S2 cell
apoptosis through mitochondrial and caspase pathways. J Korean Med
Sci. 19:560–566. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Fan YZ, Fu JY, Zhao ZM and Chen CQ:
Inhibitory effect of norcantharidin on the growth of human
gallbladder carcinoma GBC-SD cells in vitro. Hepatobiliary Pancreat
Dis Int. 6:72–80. 2007.PubMed/NCBI
|
|
36
|
Fan YZ, Zhao ZM, Fu JY, Chen CQ and Sun W:
Norcantharidin inhibits growth of human gallbladder carcinoma
xenografted tumors in nude mice by inducing apoptosis and blocking
the cell cycle in vivo. Hepatobiliary Pancreat Dis Int. 9:414–422.
2010.PubMed/NCBI
|
|
37
|
Zhang JT, Sun W, Zhang WZ, Ge CY, Liu ZY,
Zhao ZM, Lu XS and Fan YZ: Norcantharidin inhibits tumor growth and
vasculogenic mimicry of human gallbladder carcinomas by suppression
of the PI3-K/MMPs/Ln-5γ2 signaling pathway. BMC Cancer. 14:1932014.
View Article : Google Scholar
|
|
38
|
Wang H, Sun W, Zhang WZ, Ge CY, Zhang JT,
Liu ZY and Fan YZ: Inhibition of tumor vasculogenic mimicry and
prolongation of host survival in highly aggressive gallbladder
cancers by norcantharidin via blocking the ephrin type a receptor
2/focal adhesion kinase/Paxillin signaling pathway. PLoS One.
9:e969822014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
McNamara MG, Metran-Nascente C and Knox
JJ: State-of-the-art in the management of locally advanced and
metastatic gallbladder cancer. Curr Opin Oncol. 25:425–431. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Li M, Gu Y, Zhang Z, et al: Vasculogenic
mimicry: a new prognostic sign of gastric adenocarcinoma. Pathol
Oncol Res. 16:259–266. 2010. View Article : Google Scholar
|
|
41
|
Wang CJ, Zhou ZG, Holmqvist A, et al:
Survivin expression quantified by Image Pro-Plus compared with
visual assessment. Appl Immuohistochem Mol Morphol. 17:530–535.
2009. View Article : Google Scholar
|
|
42
|
Xavier LL, Viola GG, Ferraz AC, et al: A
simple and fast densitometric method for the analysis of tyrosine
hydroxylase immunoreactivity in the substantia nigra pars compacta
and in the ventral tegmental area. Brain Res Protoc. 16:58–64.
2005. View Article : Google Scholar
|
|
43
|
Situ DR, Hu Y, Zhu ZH, et al: Prognostic
relevance of β-catenin expression in T2-3N0M0 esophageal squamous
cell carcinoma. World J Gastroenterol. 16:5195–5202. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zlobec I, Steele R, Terracciano L, Jass JR
and Lugli A: Selecting immunohistochemical cut-off scores for novel
biomarkers of progression and survival in colorectal cancer. J Clin
Pathol. 60:1112–1116. 2007. View Article : Google Scholar
|
|
45
|
Kilkenny C, Browne WJ, Cuthill IC, Emerson
M and Altman DG: Improving bioscience research reporting: the
ARRIVE guidelines for reporting animal research. PLoS Biol.
8:e10004122010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Fan YZ and Sun W: Molecular regulation of
vasculogenic mimicry in tumors and potential tumor-target therapy.
World J Gastrointest Surg. 2:117–127. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Seftor RE, Seftor EA, Kirschmann DA and
Hendrix MJ: Targeting the tumor microenvironment with chemically
modified tetracyclines: inhibition of laminin 5 gamma2 chain
promigratory fragments and vasculogenic mimicry. Mol Cancer Ther.
1:1173–1179. 2002.PubMed/NCBI
|
|
48
|
Hess AR, Seftor EA, Gardner LM, et al:
Molecular regulation of tumor cell vasculogenic mimicry by tyrosine
phosphorylation: role of epithelial cell kinase (Eck/EphA2). Cancer
Res. 61:3250–3255. 2001.PubMed/NCBI
|
|
49
|
Margaryan NV, Strizzi L, Abbott DE, et al:
EphA2 as a promoter of melanoma tumorigenicity. Cancer Biol Ther.
8:279–288. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Hess AR and Hendrix MJ: Focal adhesion
kinase signaling and the aggressive melanoma phenotype. Cell Cycle.
5:478–480. 2006. View Article : Google Scholar : PubMed/NCBI
|
